CoChat
Sign Up
Cited by 124Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsAutophagy in Disease and Therapy

The DOI matches its Crossref record; 176 of the 179 references it cites were found in a registry or an index.

Senolytics for Cancer Therapy: Is All that Glitters Really Gold?

Open access
Carpenter, Valerie J., Saleh, Tareq, Gewirtz, David A.·2021·Cancers
DOI 10.3390/cancers13040723PMC PMC7916462
Open this paper in CoChat — free accountOpen PDF

Abstract

Senolytics represent a group of mechanistically diverse drugs that can eliminate senescent cells, both in tumors and in several aging-related pathologies. Consequently, senolytic use has been proposed as a potential adjuvant approach to improve the response to senescence-inducing conventional and targeted cancer therapies. Despite the unequivocal promise of senolytics, issues of universality, selectivity, resistance, and toxicity remain to be further clarified. In this review, we attempt to summarize and analyze the current preclinical literature involving the use of senolytics in senescent tumor cell models, and to propose tenable solutions and future directions to improve the understanding and use of this novel class of drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13040723

Cites

176 of 176 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Limitations of current senolytics and potential approaches for circumvention. Although senolytic agents have shown promise as adjuvant cancer therapies preclinically, careful review of the literature has elucidated common limitations. The above figure outlines four outstanding issues with current senolytics, defines these issues, and summarizes the approaches that may mitigate or circumvent these issues, as outlined in detail in Section 3.
Figure 1 Limitations of current senolytics and potential approaches for circumvention. Although senolytic agents have shown promise as adjuvant cancer therapies preclinically, careful review of the literature has elucidated common limitations. The above figure outlines four outstanding issues with current senolytics, defines these issues, and summarizes the approaches that may mitigate or circumvent these issues, as outlined in detail in Section 3.CC BY · PubMed Central
Figure 2 Validated and potential therapeutic targets to eliminate senescent cells. The accumulation of senescent cells is arguably disadvantageous to patient outcome due to the potential for proliferative recovery, the development of cell-autonomous stemness, SASP-driven stimulation of neighboring cells, and SASP-mediated immunogenicity. Despite evidence that SASP can drive immune-cell driven elimination of senescent cells, the SASP can also be strongly immunosuppressive. Further, elevated matrix-metalloprotease secretion and HLA-E expression have been demonstrated mechanisms by which senescent cells continue to evade immune cell detection. Multiple small molecule drugs have been identified and validated as senolytics (blue bolded text), but we propose that specific targeting of the more detrimental features of senescent cells (red bolded text) may prove efficacious alternatives or supplementations to the identified drug targets. This figure was generated through biorender.com.
Figure 2 Validated and potential therapeutic targets to eliminate senescent cells. The accumulation of senescent cells is arguably disadvantageous to patient outcome due to the potential for proliferative recovery, the development of cell-autonomous stemness, SASP-driven stimulation of neighboring cells, and SASP-mediated immunogenicity. Despite evidence that SASP can drive immune-cell driven elimination of senescent cells, the SASP can also be strongly immunosuppressive. Further, elevated matrix-metalloprotease secretion and HLA-E expression have been demonstrated mechanisms by which senescent cells continue to evade immune cell detection. Multiple small molecule drugs have been identified and validated as senolytics (blue bolded text), but we propose that specific targeting of the more detrimental features of senescent cells (red bolded text) may prove efficacious alternatives or supplementations to the identified drug targets. This figure was generated through biorender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 179 references

Cited by

Sorted by citations

Items 101–124 of 124

Related

See all

Metadata

Authors
Carpenter, V. J., Saleh, T., & Gewirtz, D. A.
Affiliations
  • Virginia Commonwealth University (US)
  • Hashemite University (JO)
Corresponding author
Gewirtz, David A.
ORCID
Venue
Cancers
Publisher
MDPI AG
Published
2021-02-10
Volume
13
Issue
4
Pages
723
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers13040723
PMC
PMC7916462
OpenAlex
W3128445174
Cited by
124
References
179
Citations by year
2026: 17 · 2025: 24 · 2024: 21 · 2023: 18 · 2022: 28 · 2021: 16
FWCI
2.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (CA-239706)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords
senolytics, senescent cells, cancer therapy, senescence, tumor cell models, drug selectivity, drug resistance, drug toxicity, aging, adjuvant therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review